Black Titan (BTTC) & The Competition Critical Survey

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its competitors? We will compare Black Titan to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.

Risk and Volatility

Black Titan has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.54, meaning that their average stock price is 46% less volatile than the S&P 500.

Insider & Institutional Ownership

57.9% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-64.93%	-919.57%	-68.56%

Analyst Recommendations

This is a breakdown of current ratings for Black Titan and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	205	223	14	2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 112.46%. Given Black Titan’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Black Titan has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Black Titan and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.49
Black Titan Competitors	$254.61 million	-$80.63 million	-12.44

Black Titan’s competitors have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Black Titan competitors beat Black Titan on 7 of the 13 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.